Paper36928816
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF and 18 others. Nat Med, 2023. Cited by 142 papers, by iCite.
Cite this record
ConductScience Library. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Papers, record 36928816. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36928816
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Circulating Tumor DNA | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Biomarkers, Tumor |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 37059837 | High-resolution circulating tumor DNA testing predicts survival in metastatic lung cancer clinical trials. | https://conductscience.org/library/papers/37059837 |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 2 | 22952221 | Why RECIST works and why it should stay--counterpoint. | Cancer Res | 2012 | https://conductscience.org/library/papers/22952221 | PubMed |
| 3 | 26261262 | Pseudoprogression and Immune-Related Response in Solid Tumors. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26261262 | PubMed |
| 4 | 29182990 | Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. | Eur J Cancer | 2018 | https://conductscience.org/library/papers/29182990 | PubMed |
| 5 | 31157275 | Surrogate endpoints in immunotherapy trials for solid tumors. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31157275 | PubMed |
| 6 | 30453169 | Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/30453169 | PubMed |
| 7 | 30380390 | Application of Cell-free DNA Analysis to Cancer Treatment. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380390 | PubMed |
| 8 | 28233803 | Liquid biopsies come of age: towards implementation of circulating tumour DNA. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/28233803 | PubMed |
| 9 | 31621801 | Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/31621801 | PubMed |
| 10 | 31369045 | Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/31369045 | PubMed |
| 11 | 28445469 | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. | Nature | 2017 | https://conductscience.org/library/papers/28445469 | PubMed |
| 12 | 32807235 | Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. | Genome Med | 2020 | https://conductscience.org/library/papers/32807235 | PubMed |
| 13 | 33211112 | Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2020 | https://conductscience.org/library/papers/33211112 | PubMed |
| 14 | 33659207 | Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/33659207 | PubMed |
| 15 | 34135506 | ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. | Nature | 2021 | https://conductscience.org/library/papers/34135506 | PubMed |
| 16 | 31059311 | Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31059311 | PubMed |
| 17 | 33232761 | Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. | Ann Oncol | 2021 | https://conductscience.org/library/papers/33232761 | PubMed |
| 18 | 31758080 | Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. | Sci Rep | 2019 | https://conductscience.org/library/papers/31758080 | PubMed |
| 19 | 32420063 | EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. | Transl Lung Cancer Res | 2020 | https://conductscience.org/library/papers/32420063 | PubMed |
| 20 | 35121950 | Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. | Nat Cancer | 2020 | https://conductscience.org/library/papers/35121950 | PubMed |
Cited by104
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 142 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42854587 | Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial. | ESMO Open | 2026 | https://conductscience.org/library/papers/42854587 | PubMed |
| 42803873 | Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42803873 | PubMed |
| 42724192 | Molecular differences between poorly and well/moderately differentiated lung adenocarcinoma and their clinical implications. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42724192 | PubMed |
| 42694453 | Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow? | Front Immunol | 2026 | https://conductscience.org/library/papers/42694453 | PubMed |
| 42647763 | Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42647763 | PubMed |
| 42539610 | Application of deep learning in prognostic prediction of non-small cell lung cancer. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42539610 | PubMed |
| 42532630 | Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42532630 | PubMed |
| 42416486 | Predictive value of baseline levels and early dynamic changes of ctDNA for 28-day mortality in ICU patients with advanced lung cancer: a prospective single-center cohort study. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42416486 | PubMed |
| 42395173 | Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42395173 | PubMed |
| 42353230 | The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353230 | PubMed |
| 42218435 | Extracellular vesicle and particle biomarkers in cancer: a machine learning blueprint for liquid biopsy. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42218435 | PubMed |
| 42180855 | Clinical significance of circulating tumor DNA monitoring based on TP53 mutation in high-grade serous ovarian cancer patients. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180855 | PubMed |
| 42176127 | Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42176127 | PubMed |
| 42127914 | Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42127914 | PubMed |
| 42073604 | Advances in Multi-Modal Biomarkers for Immunotherapy Response in Non-Small Cell Lung Cancer: ctDNA, Microbiome, and Radiomics. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42073604 | PubMed |
| 41878015 | Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer. | Immunotargets Ther | 2026 | https://conductscience.org/library/papers/41878015 | PubMed |
| 41859746 | Correlation Analysis Between Circulating Tumor DNA and Prognosis in Patients with Hepatocellular Carcinoma. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/41859746 | PubMed |
| 41820395 | ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/41820395 | PubMed |
| 41721022 | Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice. | Sci Rep | 2026 | https://conductscience.org/library/papers/41721022 | PubMed |
| 41649698 | Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41649698 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36928816
GET https://conductscience.org/api/papers/v1/36928816/references?page=2